Natco Pharma’s wholly owned subsidiary -- NATCO Pharma (Canada) Inc., has made an investment of $8 million in eGenesis, Inc., a biotechnology company at the forefront of xenotransplantation focused on developing safe and effective human-compatible organs for transplant. In March 2024, eGenesis announced the world’s first porcine kidney transplant in a living patient. The transplant was authorized by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway.
With this, the company is investing in new-age therapeutic programmes addressing critical unmet medical needs.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
